Clinical Trial Update: A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055) [Phase 4]

View source ↗

Summary

A Phase 4 study comparing Vernakalant to Amiodarone for the acute management of recent-onset atrial fibrillation was withdrawn from the trial registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Amiodarone (amiodarone)
• Vernakalant (vernakalant)

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Fibrillation | Phase 4 | Status: WITHDRAWN